2 Mar 2024 • Adults with persistent symptomatic asthma achieved a higher remission rate when treated with azithromycin. Remission on treatment may be an achievable treatment target in moderate/severe asthma, as per recent study findings published in the journal CHEST.

• The AMAZES trial has shed light on the potential of azithromycin alongside standard therapy as a game-changer in treating adults with persistent uncontrolled asthma.
• After 12 months of treatment, a subgroup of patients receiving azithromycin exhibited significantly higher rates of clinical remission (50.6% vs 38.9%) vs. placebo.
• In addition, a higher proportion of the azithromycin group achieved complete remission (23% vs 13.7%)
• Azithromycin induced remission in both eosinophilic and noneosinophilic asthma.

Source: CHEST | Read full story